Drug Profile
Research programme: movement disorder therapeutics - Contera Pharma
Alternative Names: JM 011; JM 013; JM 014; JM 015Latest Information Update: 10 Feb 2022
Price :
$50
*
At a glance
- Originator Contera Pharma
- Class RNA
- Mechanism of Action Glial cell modulators; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Movement disorders
Most Recent Events
- 01 Feb 2022 Preclinical trials in Movement disorders is ongoing in Denmark (Contera Pharma pipeline, February 2022)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Movement-disorders in Denmark
- 18 Aug 2015 Preclinical trials in Movement disorders in Denmark (unspecified route) before August 2015